NCT07194850View on ClinicalTrials.gov

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 29, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2030

Conditions
Immune Thrombocytopenia (ITP)ITP - Immune ThrombocytopeniaITPImmune Thrombocytopenic PurpuraImmune Thrombocytopenic Purpura ( ITP )Idiopathic Thrombocytopenic PurpuraIdiopathic Thrombocytopenic Purpura (ITP)
Interventions
BIOLOGICAL

Efgartigimod IV

Intravenous infusion of efgartigimod

OTHER

Placebo IV

Intravenous infusion of placebo

Sponsors

Lead Sponsor

argenx
All Listed Sponsors
lead

argenx

INDUSTRY